Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report
| Autor: | Akira Mogi, Ayako Yamazaki, Ryoichi Onozato, Kenji Tomizawa, Ei Yamaki, Toshiki Yajima, Ken Shirabe, Junko Hirato, Yasushi Yatabe, Kimihiro Shimizu, Seshiru Nakazawa, Takayuki Kosaka |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
Lung Crizotinib Oncogene business.industry medicine.drug_class Cancer medicine.disease Molecular medicine respiratory tract diseases ALK inhibitor 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Oncology hemic and lymphatic diseases 030220 oncology & carcinogenesis Cancer research Medicine Anaplastic lymphoma kinase Adenocarcinoma 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Molecular and Clinical Oncology. |
| ISSN: | 2049-9469 2049-9450 |
| Popis: | Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK-rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an important factor in guiding the treatment strategy for ALK-rearranged lung adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|